Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 402

1.

Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors.

Grenader T, Pavel ME, Ruszniewski PB, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Truong Thanh XM, Caplin ME; CLARINET Study Group.

Anticancer Drugs. 2020 Jan 21. doi: 10.1097/CAD.0000000000000909. [Epub ahead of print]

PMID:
31977567
2.

The postoperative occurrence or worsening of diabetes mellitus may increase the risk of recurrence in resected pancreatic neuroendocrine tumors.

de Mestier L, Védie AL, Faron M, Cros J, Rebours V, Hentic O, Do Cao C, Bardet P, Lévy P, Sauvanet A, Ruszniewski P, Hammel P.

Neuroendocrinology. 2019 Dec 3. doi: 10.1159/000505158. [Epub ahead of print]

PMID:
31791037
3.

Risk factors and treatment of relapses in autoimmune pancreatitis: Rituximab is safe and effective.

Soliman H, Vullierme MP, Maire F, Hentic O, Ruszniewski P, Lévy P, Rebours V.

United European Gastroenterol J. 2019 Oct;7(8):1073-1083. doi: 10.1177/2050640619862459. Epub 2019 Jul 3.

4.

Natural history of SPINK1 germline mutation related-pancreatitis.

Muller N, Sarantitis I, Rouanet M, de Mestier L, Halloran C, Greenhalf W, Férec C, Masson E, Ruszniewski P, Lévy P, Neoptolemos J, Buscail L, Rebours V.

EBioMedicine. 2019 Oct;48:581-591. doi: 10.1016/j.ebiom.2019.09.032. Epub 2019 Oct 15.

5.

Implementation of a large-scale simulation-based cardiovascular clinical examination course for undergraduate medical students - a pilot study.

Arangalage D, Abtan J, Gaschignard J, Ceccaldi PF, Remini SA, Etienne I, Ruszniewski P, Plaisance P, De Lastours V, Lefort A, Faye A.

BMC Med Educ. 2019 Sep 18;19(1):361. doi: 10.1186/s12909-019-1750-4.

6.

Unmet needs in the international neuroendocrine tumor (NET) community: Assessment of major gaps from the perspective of patients, patient advocates and NET health care professionals.

Leyden S, Kolarova T, Bouvier C, Caplin M, Conroy S, Davies P, Dureja S, Falconi M, Ferolla P, Fisher G, Goldstein G, Hicks RJ, Lawrence B, Majima Y, Metz DC, O'Toole D, Ruszniewski P, Wiedenmann B, Hollander R; International Neuroendocrine Cancer Alliance (INCA).

Int J Cancer. 2020 Mar 1;146(5):1316-1323. doi: 10.1002/ijc.32678. Epub 2019 Oct 25.

PMID:
31509608
7.

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.

Kulke MH, Ruszniewski P, Van Cutsem E, Lombard-Bohas C, Valle JW, De Herder WW, Pavel M, Degtyarev E, Brase JC, Bubuteishvili-Pacaud L, Voi M, Salazar R, Borbath I, Fazio N, Smith D, Capdevila J, Riechelmann RP, Yao JC.

Ann Oncol. 2019 Nov 1;30(11):1846. doi: 10.1093/annonc/mdz219. No abstract available.

PMID:
31407000
8.

The ENETS TNM staging and grading system accurately predict prognosis in patients with rectal NENs.

Capurso G, Gaujoux S, Pescatori LC, Panzuto F, Panis Y, Pilozzi E, Terris B, de Mestier L, Prat F, Rinzivillo M, Coriat R, Coulevard A, Delle Fave G, Ruszniewski P.

Dig Liver Dis. 2019 Dec;51(12):1725-1730. doi: 10.1016/j.dld.2019.07.011. Epub 2019 Aug 9.

PMID:
31405587
9.

Lesion-by-lesion correlation between uptake at FDG PET and the Ki67 proliferation index in resected pancreatic neuroendocrine tumors.

de Mestier L, Armani M, Cros J, Hentic O, Rebours V, Cadiot G, Sauvanet A, Couvelard A, Lebtahi R, Ruszniewski P.

Dig Liver Dis. 2019 Dec;51(12):1720-1724. doi: 10.1016/j.dld.2019.06.022. Epub 2019 Jul 23.

PMID:
31350186
10.

Endoscopic, transanal, laparoscopic, and transabdominal management of rectal neuroendocrine tumors.

de Mestier L, Lorenzo D, Fine C, Cros J, Hentic O, Walter T, Panis Y, Couvelard A, Cadiot G, Ruszniewski P.

Best Pract Res Clin Endocrinol Metab. 2019 Oct;33(5):101293. doi: 10.1016/j.beem.2019.101293. Epub 2019 Jul 9. Review.

PMID:
31326374
11.

Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor.

de Mestier L, Walter T, Evrard C, de Boissieu P, Hentic O, Cros J, Tougeron D, Lombard-Bohas C, Rebours V, Hammel P, Ruszniewski P.

Neuroendocrinology. 2020;110(1-2):83-91. doi: 10.1159/000500862. Epub 2019 May 10.

12.

Non-branched microcysts of the pancreas on MR imaging of patients with pancreatic tumors who had pancreatectomy may predict the presence of pancreatic intraepithelial neoplasia (PanIN): a preliminary study.

Vullierme MP, Menassa L, Couvelard A, Rebours V, Maire F, Ibrahim T, Cros J, Ruszniewski P, Sauvanet A, Levy P, Soyer P, Vilgrain V.

Eur Radiol. 2019 Nov;29(11):5731-5741. doi: 10.1007/s00330-019-06154-3. Epub 2019 Apr 10.

PMID:
30972547
13.

Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses.

de Mestier L, Walter T, Brixi H, Evrard C, Legoux JL, de Boissieu P, Hentic O, Cros J, Hammel P, Tougeron D, Lombard-Bohas C, Rebours V, Ruszniewski P, Cadiot G.

Neuroendocrinology. 2019;108(4):343-353. doi: 10.1159/000498887. Epub 2019 Feb 13.

PMID:
30759445
14.

Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors.

Dromain C, Pavel ME, Ruszniewski P, Langley A, Massien C, Baudin E, Caplin ME; CLARINET Study Group.

BMC Cancer. 2019 Jan 14;19(1):66. doi: 10.1186/s12885-018-5257-x.

15.

Metastatic Potential and Survival of Duodenal and Pancreatic Tumors in Multiple Endocrine Neoplasia Type 1: A GTE and AFCE Cohort Study (Groupe d'étude des Tumeurs Endocrines and Association Francophone de Chirurgie Endocrinienne).

Vinault S, Mariet AS, Le Bras M, Mirallié E, Cardot-Bauters C, Pattou F, Ruszniewski P, Sauvanet A, Chanson P, Baudin E, Elias D, Menegaux F, Gaujoux S, Borson-Chazot F, Lifante JC, Caron P, Carrère N, Tabarin A, Laurent C, Klein M, Brunaud L, Niccoli P, Sebag F, Cadiot G, Kianmanesh R, Luu M, Binquet C, Goudet P.

Ann Surg. 2018 Dec 21. doi: 10.1097/SLA.0000000000003162. [Epub ahead of print]

PMID:
30585820
16.

Obesity-induced pancreatopathy in rats is reversible after bariatric surgery.

Rebours V, Garteiser P, Ribeiro-Parenti L, Cavin JB, Doblas S, Pagé G, Bado A, Couvineau A, Ruszniewski P, Paradis V, Le Gall M, Van Beers BE, Couvelard A.

Sci Rep. 2018 Nov 2;8(1):16295. doi: 10.1038/s41598-018-34515-3.

17.

Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort Study.

Rindi G, Klersy C, Albarello L, Baudin E, Bianchi A, Buchler MW, Caplin M, Couvelard A, Cros J, de Herder WW, Delle Fave G, Doglioni C, Federspiel B, Fischer L, Fusai G, Gavazzi F, Hansen CP, Inzani F, Jann H, Komminoth P, Knigge UP, Landoni L, La Rosa S, Lawlor RT, Luong TV, Marinoni I, Panzuto F, Pape UF, Partelli S, Perren A, Rinzivillo M, Rubini C, Ruszniewski P, Scarpa A, Schmitt A, Schinzari G, Scoazec JY, Sessa F, Solcia E, Spaggiari P, Toumpanakis C, Vanoli A, Wiedenmann B, Zamboni G, Zandee WT, Zerbi A, Falconi M.

Neuroendocrinology. 2018;107(4):375-386. doi: 10.1159/000494355. Epub 2018 Oct 9.

18.

Predicting the efficacy of surgery for pain relief in patients with alcoholic chronic pancreatitis.

Bordaçahar B, Couvelard A, Vullierme MP, Bucchini L, Sauvanet A, Dokmak S, Ruszniewski P, Lévy P, Rebours V.

Surgery. 2018 Nov;164(5):1064-1070. doi: 10.1016/j.surg.2018.05.025. Epub 2018 Jul 18.

PMID:
30029988
19.

Biomarkers for the risk of thrombosis in pancreatic adenocarcinoma are related to cancer process.

Faille D, Bourrienne MC, de Raucourt E, de Chaisemartin L, Granger V, Lacroix R, Panicot-Dubois L, Hammel P, Lévy P, Ruszniewski P, Ajzenberg N, Rebours V.

Oncotarget. 2018 May 29;9(41):26453-26465. doi: 10.18632/oncotarget.25458. eCollection 2018 May 29.

20.

Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial.

Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday T, Hendifar A, Oberg K, Sierra ML, Thevenet T, Margalet I, Ruszniewski P, Krenning E; NETTER-1 Study Group.

J Clin Oncol. 2018 Sep 1;36(25):2578-2584. doi: 10.1200/JCO.2018.78.5865. Epub 2018 Jun 7.

21.

Perspectives of patients and physicians about neuroendocrine tumors. A qualitative study.

Sibeoni J, Khannoussi W, Manolios E, Rebours V, Revah-Levy A, Ruszniewski P.

Oncotarget. 2018 Jan 31;9(18):14138-14147. doi: 10.18632/oncotarget.24347. eCollection 2018 Mar 6.

22.

Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms.

Pellat A, Dreyer C, Couffignal C, Walter T, Lombard-Bohas C, Niccoli P, Seitz JF, Hentic O, André T, Coriat R, Faivre S, Zappa M, Ruszniewski P, Pote N, Couvelard A, Raymond E.

Neuroendocrinology. 2018;107(1):24-31. doi: 10.1159/000487237. Epub 2018 Mar 8.

PMID:
29518779
23.

In vitro, in vivo and ex vivo demonstration of the antitumoral role of hypocretin-1/orexin-A and almorexant in pancreatic ductal adenocarcinoma.

Dayot S, Speisky D, Couvelard A, Bourgoin P, Gratio V, Cros J, Rebours V, Sauvanet A, Bedossa P, Paradis V, Ruszniewski P, Couvineau A, Voisin T.

Oncotarget. 2018 Jan 9;9(6):6952-6967. doi: 10.18632/oncotarget.24084. eCollection 2018 Jan 23.

24.

Contrast harmonic EUS for the prediction of pancreatic neuroendocrine tumor aggressiveness (with videos).

Palazzo M, Napoléon B, Gincul R, Pioche M, Pujol B, Lefort C, Fumex F, Hautefeuille V, Fabre M, Cros J, Felce M, Couvelard A, Sauvanet A, Lévy P, Ruszniewski P, Palazzo L.

Gastrointest Endosc. 2018 Jun;87(6):1481-1488. doi: 10.1016/j.gie.2017.12.033. Epub 2018 Jan 8.

PMID:
29325706
25.

Prognosis of sporadic resected small (≤2 cm) nonfunctional pancreatic neuroendocrine tumors - a multi-institutional study.

Sallinen VJ, Le Large TYS, Tieftrunk E, Galeev S, Kovalenko Z, Haugvik SP, Antila A, Franklin O, Martinez-Moneo E, Robinson SM, Panzuto F, Regenet N, Muffatti F, Partelli S, Wiese D, Ruszniewski P, Dousset B, Edwin B, Bartsch DK, Sauvanet A, Falconi M, Ceyhan GO, Gaujoux S; Pancreas 2000 research group.

HPB (Oxford). 2018 Mar;20(3):251-259. doi: 10.1016/j.hpb.2017.08.034. Epub 2017 Oct 5.

26.

Liver transarterial embolizations in metastatic neuroendocrine tumors.

de Mestier L, Zappa M, Hentic O, Vilgrain V, Ruszniewski P.

Rev Endocr Metab Disord. 2017 Dec;18(4):459-471. doi: 10.1007/s11154-017-9431-2. Review.

PMID:
28975561
27.

Recommendations on managing lenvatinib and everolimus in patients with advanced or metastatic renal cell carcinoma.

Grande E, Glen H, Aller J, Argenziano G, Lamas MJ, Ruszniewski P, Zamorano JL, Edmonds K, Sarker S, Staehler M, Larkin J.

Expert Opin Drug Saf. 2017 Dec;16(12):1413-1426. doi: 10.1080/14740338.2017.1380624. Epub 2017 Sep 28. Review.

PMID:
28920492
28.

18F-FDG Uptake in Well-Differentiated Neuroendocrine Tumors Correlates with Both Ki-67 and VHL Pathway Inactivation.

Bucau M, Laurent-Bellue A, Poté N, Hentic O, Cros J, Mikail N, Rebours V, Ruszniewski P, Lebtahi R, Couvelard A.

Neuroendocrinology. 2018;106(3):274-282. doi: 10.1159/000480239. Epub 2017 Aug 11.

PMID:
28803235
29.

Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms.

de Mestier L, Cros J, Neuzillet C, Hentic O, Egal A, Muller N, Bouché O, Cadiot G, Ruszniewski P, Couvelard A, Hammel P.

Neuroendocrinology. 2017;105(4):412-425. doi: 10.1159/000475527. Epub 2017 Aug 12. Review.

30.

Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours.

Neuzillet C, de Mestier L, Rousseau B, Mir O, Hebbar M, Kocher HM, Ruszniewski P, Tournigand C.

Pharmacol Ther. 2018 Jan;181:49-75. doi: 10.1016/j.pharmthera.2017.07.006. Epub 2017 Jul 16. Review.

PMID:
28723416
31.

Management of gastric neuro-endocrine tumours in a large French national cohort (GTE).

Manfredi S, Walter T, Baudin E, Coriat R, Ruszniewski P, Lecomte T, Laurenty AP, Goichot B, Rohmer V, Roquin G, Cojocarasu OZ, Lombard-Bohas C, Lepage C, Morcet J, Cadiot G.

Endocrine. 2017 Sep;57(3):504-511. doi: 10.1007/s12020-017-1355-9. Epub 2017 Jun 29.

32.

Estimation of the prevalence of intraductal papillary mucinous neoplasm of the pancreas in the French population through patients waiting for liver transplantation.

Laurent L, Vullierme MP, Rebours V, Maire F, Hentic O, Francoz C, Durand F, Ruszniewski P, Lévy P.

United European Gastroenterol J. 2017 Jun;5(4):499-503. doi: 10.1177/2050640616664842. Epub 2016 Aug 16.

33.

Epidemiology of pancreatic cancer in France: descriptive study from the French national hospital database.

Maire F, Cibot JO, Compagne C, Hentic O, Hammel P, Muller N, Ponsot P, Levy P, Ruszniewski P.

Eur J Gastroenterol Hepatol. 2017 Aug;29(8):904-908. doi: 10.1097/MEG.0000000000000901.

PMID:
28471829
34.

The Largest European Single-Center Experience: 300 Laparoscopic Pancreatic Resections.

Dokmak S, Ftériche FS, Aussilhou B, Lévy P, Ruszniewski P, Cros J, Vullierme MP, Khoy Ear L, Belghiti J, Sauvanet A.

J Am Coll Surg. 2017 Aug;225(2):226-234.e2. doi: 10.1016/j.jamcollsurg.2017.04.004. Epub 2017 Apr 13.

PMID:
28414116
35.

ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Biochemical Markers.

Oberg K, Couvelard A, Delle Fave G, Gross D, Grossman A, Jensen RT, Pape UF, Perren A, Rindi G, Ruszniewski P, Scoazec JY, Welin S, Wiedenmann B, Ferone D; Antibes Consensus Conference participants.

Neuroendocrinology. 2017;105(3):201-211. doi: 10.1159/000472254. Epub 2017 Apr 8. No abstract available.

36.

Antisecretory Effects of Chimeric Somatostatin/Dopamine Receptor Ligands on Gastroenteropancreatic Neuroendocrine Tumors.

Couvelard A, Pélaprat D, Dokmak S, Sauvanet A, Voisin T, Couvineau A, Ruszniewski P.

Pancreas. 2017 May/Jun;46(5):631-638. doi: 10.1097/MPA.0000000000000813.

PMID:
28375946
37.

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.

Kulke MH, Ruszniewski P, Van Cutsem E, Lombard-Bohas C, Valle JW, De Herder WW, Pavel M, Degtyarev E, Brase JC, Bubuteishvili-Pacaud L, Voi M, Salazar R, Borbath I, Fazio N, Smith D, Capdevila J, Riechelmann RP, Yao JC.

Ann Oncol. 2017 Jun 1;28(6):1309-1315. doi: 10.1093/annonc/mdx078.

38.

Neuroendocrine liver metastases: Vascular patterns on triple-phase MDCT are indicative of primary tumour location.

Ronot M, Cuccioli F, Dioguardi Burgio M, Vullierme MP, Hentic O, Ruszniewski P, d'Assignies G, Vilgrain V.

Eur J Radiol. 2017 Apr;89:156-162. doi: 10.1016/j.ejrad.2017.02.007. Epub 2017 Feb 9.

PMID:
28267533
39.

Long-term Follow-up of MEN1 Patients Who Do Not Have Initial Surgery for Small ≤2 cm Nonfunctioning Pancreatic Neuroendocrine Tumors, an AFCE and GTE Study: Association Francophone de Chirurgie Endocrinienne & Groupe d'Etude des Tumeurs Endocrines.

Triponez F, Sadowski SM, Pattou F, Cardot-Bauters C, Mirallié E, Le Bras M, Sebag F, Niccoli P, Deguelte S, Cadiot G, Poncet G, Lifante JC, Borson-Chazot F, Chaffanjon P, Chabre O, Menegaux F, Baudin E, Ruszniewski P, Du Boullay H, Goudet P.

Ann Surg. 2018 Jul;268(1):158-164. doi: 10.1097/SLA.0000000000002191.

40.

ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours.

Partelli S, Bartsch DK, Capdevila J, Chen J, Knigge U, Niederle B, Nieveen van Dijkum EJM, Pape UF, Pascher A, Ramage J, Reed N, Ruszniewski P, Scoazec JY, Toumpanakis C, Kianmanesh R, Falconi M; Antibes Consensus Conference participants.

Neuroendocrinology. 2017;105(3):255-265. doi: 10.1159/000464292. Epub 2017 Feb 25. No abstract available.

PMID:
28237989
41.

Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE).

Roquin G, Baudin E, Lombard-Bohas C, Cadiot G, Dominguez S, Guimbaud R, Niccoli P, Legoux JL, Mitry E, Rohmer V, Ruszniewski P, Walter T, Ducreux M, Couvelard A, Scoazec JY, Ramond-Roquin A, Caroli-Bosc FX, Hentic O.

Neuroendocrinology. 2018;106(1):38-46. doi: 10.1159/000457955. Epub 2017 Feb 3.

42.

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators.

N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427.

43.

Is visual radiological evaluation of liver tumour burden in patients with neuroendocrine tumours reproducible?

Zappa M, Hentic O, Vullierme MP, Lagadec M, Ronot M, Ruszniewski P, Vilgrain V.

Endocr Connect. 2017 Jan;6(1):33-38. doi: 10.1530/EC-16-0092. Epub 2017 Jan 9.

44.

Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study.

Faivre S, Niccoli P, Castellano D, Valle JW, Hammel P, Raoul JL, Vinik A, Van Cutsem E, Bang YJ, Lee SH, Borbath I, Lombard-Bohas C, Metrakos P, Smith D, Chen JS, Ruszniewski P, Seitz JF, Patyna S, Lu DR, Ishak KJ, Raymond E.

Ann Oncol. 2017 Feb 1;28(2):339-343. doi: 10.1093/annonc/mdw561.

45.

DNA integrity as biomarker in pancreatic cyst fluid.

Utomo WK, Janmaat VT, Verhaar AP, Cros J, Lévy P, Ruszniewski P, den Berg MS, Jenster G, Bruno MJ, Braat H, Fuhler GM, Peppelenbosch MP.

Am J Cancer Res. 2016 Aug 1;6(8):1837-41. eCollection 2016.

46.

Accuracy of 2012 International Consensus Guidelines for the prediction of malignancy of branch-duct intraductal papillary mucinous neoplasms of the pancreas.

Robles EP, Maire F, Cros J, Vullierme MP, Rebours V, Sauvanet A, Aubert A, Dokmak S, Lévy P, Ruszniewski P.

United European Gastroenterol J. 2016 Aug;4(4):580-6. doi: 10.1177/2050640615623370. Epub 2016 Jan 6.

47.

Long-Term Retrospective Analysis of Gene Therapy with Alipogene Tiparvovec and Its Effect on Lipoprotein Lipase Deficiency-Induced Pancreatitis.

Gaudet D, Stroes ES, Méthot J, Brisson D, Tremblay K, Bernelot Moens SJ, Iotti G, Rastelletti I, Ardigo D, Corzo D, Meyer C, Andersen M, Ruszniewski P, Deakin M, Bruno MJ.

Hum Gene Ther. 2016 Nov;27(11):916-925. Epub 2016 Jul 13.

PMID:
27412455
48.

Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.

Coriat R, Walter T, Terris B, Couvelard A, Ruszniewski P.

Oncologist. 2016 Oct;21(10):1191-1199. Epub 2016 Jul 8. Review.

49.

MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors.

Cros J, Hentic O, Rebours V, Zappa M, Gille N, Theou-Anton N, Vernerey D, Maire F, Lévy P, Bedossa P, Paradis V, Hammel P, Ruszniewski P, Couvelard A.

Endocr Relat Cancer. 2016 Aug;23(8):625-33. doi: 10.1530/ERC-16-0117. Epub 2016 Jun 28.

PMID:
27353036
50.

OC-06 - Pro-thrombotic biomarkers in pancreatic diseases: are they specific of cancer?

Faille D, Ajzenberg N, de Chaisemartin L, Granger V, Chollet-Martin S, de Raucourt E, Hammel P, Lévy P, Ruszniewski P, Rebours V.

Thromb Res. 2016 Apr;140 Suppl 1:S170-1. doi: 10.1016/S0049-3848(16)30123-2. Epub 2016 Apr 8.

PMID:
27161678

Supplemental Content

Loading ...
Support Center